RenovoRx, Inc.
RNXTNasdaq
$0.87
↓ -1.8%Jul 17 close · end-of-day
Price
1Y↓ -33.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$32.9M
Enterprise Value
$20.5M
P/E
—
P/S
22.1
P/B
2.9
EV/EBITDA
—
PEG
—
FCF Yield
-34.3%
Dividend Yield
—
Revenue (TTM)
$1.5M
Net Income (TTM)
-$12.3M
Free Cash Flow (TTM)
-$11.3M
Gross Margin
78.7%
Operating Margin
-864.3%
Net Margin
-824.0%
ROE
-108.9%
ROIC
—
Debt / Equity
—
Net Cash
$12.4M
Return 1Y
-33.4%
Company profile
RenovoRx, Inc. focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.
- CEO
- Shaun R. Bagai
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 6
- Headquarters
- California
- Website
- www.renovorx.com
Management & directors
- Voll MarkChief Financial Officer
- Bagai ShaunChief Executive Officer
- Agah RamtinChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
RNXT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$563,000.00↑ +185.8%
Diluted EPS-$0.09↑ +12.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $43,000.00 | $1.1M |
| Gross profit | — | — | — | — | $43,000.00 | $796,000.00 |
| Operating income | -$3.2M | -$5.7M | -$9.9M | -$11.4M | -$11.0M | -$12.5M |
| Net income | -$3.8M | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
| Diluted EPS | — | — | -$1.09 | -$0.99 | -$0.40 | -$0.32 |
| Operating cash flow | -$3.5M | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M |
| Free cash flow | — | — | — | — | -$9.1M | -$11.0M |
| Gross margin | — | — | — | — | 100.0% | 70.9% |
| Operating margin | — | — | — | — | -25511.6% | -1114.0% |
| Net margin | — | — | — | — | -20497.7% | -994.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $197,000.00 | $422,000.00 | $266,000.00 | $238,000.00 | $563,000.00 |
| Gross profit | — | — | — | $103,000.00 | $270,000.00 | $213,000.00 | $210,000.00 | $479,000.00 |
| Operating income | -$3.0M | -$2.8M | -$2.6M | -$3.1M | -$2.7M | -$3.2M | -$3.5M | -$3.5M |
| Net income | -$2.4M | -$2.5M | -$2.9M | -$2.4M | -$2.9M | -$2.9M | -$2.9M | -$3.5M |
| Diluted EPS | -$0.10 | -$0.10 | -$0.13 | -$0.08 | -$0.08 | -$0.08 | -$0.08 | -$0.09 |
| Operating cash flow | -$2.3M | -$2.2M | -$2.4M | -$3.4M | -$2.3M | -$2.3M | -$3.0M | -$3.7M |
| Free cash flow | — | — | — | -$3.4M | -$2.3M | -$2.3M | -$3.0M | -$3.7M |
| Gross margin | — | — | — | 52.3% | 64.0% | 80.1% | 88.2% | 85.1% |
| Operating margin | — | — | — | -1578.7% | -634.6% | -1203.0% | -1479.8% | -616.2% |
| Net margin | — | — | — | -1228.4% | -686.0% | -1094.7% | -1235.7% | -625.4% |
Company news
Jun 23, 2026
Jun 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-19 | VOLL MARK· Chief Financial Officer | Buy | 25,000 | $0.79 | $19,690.00 | filing |
| 2026-04-03 | VOLL MARK· Chief Financial Officer | Award | 80,000 | $0.00 | $0.00 | filing |
| 2026-03-25 | VOLL MARK· Chief Financial Officer | Award | 12,380 | $0.00 | $0.00 | filing |
| 2026-03-20 | Marton Laurence | Buy | 9,720 | — | — | filing |
| 2026-03-20 | Bagai Shaun· Chief Executive Officer | Buy | 24,300 | — | — | filing |
| 2026-03-20 | VOLL MARK· Chief Financial Officer | Buy | 97,200 | — | — | filing |
| 2026-01-21 | Agah Ramtin· Chief Medical Officer | Buy | 10,000 | $1.00 | $9,975.00 | filing |
| 2025-12-31 | Agah Ramtin· Chief Medical Officer | Buy | 9,795 | $0.86 | $8,423.70 | filing |
| 2025-12-30 | Agah Ramtin· Chief Medical Officer | Buy | 205 | $0.83 | $169.33 | filing |
| 2025-12-18 | Bagai Shaun· Chief Executive Officer | Buy | 5,000 | $0.90 | $4,506.50 | filing |
| 2025-12-17 | Bagai Shaun· Chief Executive Officer | Buy | 5,000 | $0.85 | $4,262.00 | filing |
| 2025-12-16 | Agah Ramtin· Chief Medical Officer | Buy | 12,000 | $0.85 | $10,200.00 | filing |
| 2025-12-05 | Agah Ramtin· Chief Medical Officer | Buy | 10,000 | $0.96 | $9,600.00 | filing |
| 2025-12-05 | Agah Ramtin· Chief Medical Officer | Buy | 10,000 | $0.96 | $9,600.00 | filing |
| 2025-11-24 | Agah Ramtin· Chief Medical Officer | Buy | 12,000 | $0.80 | $9,600.00 | filing |
| 2025-11-21 | Agah Ramtin· Chief Medical Officer | Buy | 10,000 | $0.80 | $8,000.00 | filing |
| 2025-08-25 | Bagai Shaun· Chief Executive Officer | Buy | 5,000 | $0.91 | $4,549.00 | filing |
| 2025-08-22 | Bagai Shaun· Chief Executive Officer | Buy | 5,000 | $0.95 | $4,747.50 | filing |
Latest 18 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.